Multiple sclerosis (MS) is a debilitating neuroimmunological and neurodegenerative disease with a strong genetic component. Numerous studies have failed to consistently identify genes that confer disease susceptibility except for association with HLA-DR. Seven non-HLA regions (1q, 2q, 9q, 13q, 16q, 18p and 19q) identified in a recent genomic screen were investigated by genotyping B20 single-nucleotide polymorphisms (SNPs) at B1 Mb intervals. Non-parametric multipoint analyses identified a peak LOD* score of 2.99 for the 1q44 region and substantially narrowed the linkage peak to B7 Mb. Ordered subset analyses (OSA) identified significant LOD score increases for 2q35 and 18p11 when ranking families by HLA-DR status and identified a significant LOD score increase in region 2q35 when ranking families by linkage to chromosome 1q44. 1q44 is particularly interesting because of linkage evidence for this region in studies of both rheumatoid arthritis and systemic lupus erythematosus.
Multiple sclerosis (MS) is a debilitating neuroimmunological and neurodegenerative disease (MS [MIM 126200]) and is estimated to affect 400 000 individuals in the United States alone. Numerous population and family-based studies suggest that genes play a vital role in disease risk. Like most common complex diseases, susceptibility to MS is suspected to be the result of multiple genes acting either independently or interactively in their contribution to overall risk.
MS exhibits several characteristics that are common to autoimmune diseases including polygenic inheritance, evidence of environmental exposure, increased frequency in women, and partial susceptibility conferred by a human leukocyte antigen (HLA)-associated gene. 1 Despite substantial evidence for polygenic inheritance, the major histocompatibility complex (MHC) containing HLA is the only region that has clearly and consistently demonstrated linkage and association in MS genetic studies.
Multiple genomic screens have nominated over 70 regions for harboring MS loci but almost all studies have lacked sufficient power to identify loci of moderate effect with statistically significant results. Although it is probable that several of the regions identified in these genomic screens do contain MS loci, the failure to replicate results in multiple screens or in follow-up studies is problematic. We recently completed the largest genomic screen to date for MS in conjunction with the French Multiple Sclerosis Genetics Group. In addition to the HLA-DR locus, the strongest signals from the screen were generated in regions 1q, 2q, 9q, 13q, 16q and 18p (HLOD scores and/ or Z scores 42.0). 2 We further investigated these six non-HLA regions using an expanded US data set (Table 1) and increased marker coverage with SNPs. Although 19q did not meet the formal criterion for further interest in the screen, this region is frequently observed in linkage studies for MS and was also investigated.
A list of peak two-point, multipoint, and HLAconditional LOD scores for each follow-up region is provided in Table 2 . Chromosome 1q44 demonstrated the strongest evidence of linkage after follow-up, with markers replicating peak scores o1 Mb from the original peak genomic screen marker. Two-point analysis generated a peak HLOD score of 2.60 in the overall data setgreater than the peak HLOD score observed in the genomic screen. Multipoint analysis generated a peak multipoint LOD* score of 2.99 in the overall data set and substantially narrowed the interval of interest in this region to B7 Mb with a LOD -1.0 confidence interval ( Figure 1 ). Ordered subset analysis (OSA) generated peak LOD scores greater than multipoint scores for the overall data set with OSA maxLOD scores ranging from 3.47 to 4.54. However, the OSA analysis also failed to differentiate specific subsets accounting for the genetic effect in this region, as no LOD score increases were statistically significant. Two-point analysis identified five markers in the 2q35 region with HLOD scores 41.0, all of which were identified in families without an HLA-DR2 allele. Whereas chromosome 2q35 did not demonstrate substantial evidence of linkage in multipoint calculations for the overall data set, OSA analysis generated a significantly increased maxLOD score of 1.86 at B194 Mb in the HLA-DR LOD score Low to High ranking (15 families; P ¼ 0.03). OSA analysis also generated a significantly increased maxLOD score of 2.20 at B191 Mb in the chromosome 1 LOD* score High to Low ranking (22 families; P ¼ 0.01) ( Figure 2 ).
Chromosome 9q34 demonstrated only modest evidence of linkage in two-point and multipoint analyses. OSA analysis increased the peak maxLOD score for this region in the HLA-DR LOD Low to High ranking, but with only a trend toward significance (maxLOD ¼ 1.81; 91 families; P ¼ 0.09).
Chromosome 13q11 failed to demonstrate any evidence of linkage in the multipoint analyses. However, the highest two-point (HLOD ¼ 1.36) and OSA (maxLOD ¼ 1.08 in the chromosome 1 LOD* Low to High subset; P ¼ 0.09) LOD scores for this region were generated adjacent to the peak microsatellite marker for 13q11 in the genomic screen.
Chromosome 16q23 generated a peak multipoint LOD* score of 0.51 in the overall data set. OSA analysis generated a peak maxLOD score of 1.83 in the chromosome 1 LOD* High to Low ranking (34 families; P ¼ 0.14), but did not significantly increase LOD scores or The data set consisted of US families from our recently published genomic screen 2 and 29 newly ascertained US families (containing 11 affected sib-pairs, 56 discordant sib-pairs, and 23 other affected relative pairs). Families were ascertained by the University of California at San Francisco (UCSF) as previously described. 2 All protocols were approved by the appropriate Institutional Review Boards and all individuals provided informed consent before participating in the study. Families were designated HLA-DR2+ if every affected individual carried at least one HLA-DR2 allele or designated HLA-DR2À if no affected individuals carried an HLA-DR2 allele. Allele frequencies were calculated from the genotyped founders in each family. Hardy-Weinberg calculations were performed for each marker and Mendelian inconsistencies were identified using PedCheck. 24 Improbable double recombination events were identified using SIMWALK version 2.9.
25 Suspect genotypes were re-read and/or re-run. All SNPs were required to have 490% of possible genotypes. Verification of relationships between pairs of samples within families was performed using RELPAIR. 26 Markers and samples failing to pass quality control measures were dropped from the analysis. Model-based analyses were conducted using autosomal dominant and autosomal recessive models as previously described.
2 Two-point LOD scores were calculated in FASTLINK 27, 28 and two-point heterogeneity LOD (HLOD) scores were calculated in HOMOG. 29, 30 Multipoint LOD scores were calculated in Allegro and are reported as LOD* scores. 31 SNP markers and individual LOD scores are available online (see Vanderbilt Center for Human Genetics website, http://chgr.mc.vanderbilt.edu/ publications.html). Seven candidate regions for multiple sclerosis SJ Kenealy et al differentiate linkage contribution from any of the optimal HLA-DR subsets. Two-point analysis identified two markers in the 18p11 region with HLOD scores 4 1.0. Multipoint analysis generated a peak LOD* score of 0.75 in the overall data set. The OSA analysis demonstrated a statistically significant increase in evidence of linkage with a maxLOD score of 1.91 in the HLA-DR2-Weight Low to High ranked families (165 families; P ¼ 0.02) (Figure 3) . OSA also generated an increased LOD score with a trend toward significance in the chromosome 1 LOD* Low to High subset (maxLOD ¼ 2.14; 126 families; P ¼ 0.09) (Figure 3) .
Chromosome 19q13 generated peak multipoint scores at the same Mb location for the overall dataset and in families with at least one HLA-DR2 allele in each affected individual (LOD* ¼ 0.86 and LOD* ¼ 0.85, respectively). However, OSA analyses failed to generate even moderate P-values for any of the ranking strategies.
Traditional follow-up of genomic screen results entails genotyping additional microsatellite markers located at smaller genetic intervals than the original screen markers. Whereas this approach can be effective, we chose to follow up our genomic screen results with a denser map of SNPs. With higher throughput capabilities and more accurate genotypes, SNPs allowed for expedited genotyping and improved quality control of our data. The information content increased to over 80% using these markers and provided thorough coverage of each region and substantially increased the effective size of our data set by 35%.
3 Follow-up with SNPs located at 1 Mb intervals resulted in higher quality data, greater information extraction, and substantially narrowed linkage peaks in several of our regions of interest.
Our strongest linkage result arises on chromosome 1q44, where the multipoint LOD score increased relative to the initial genomic screen. In addition to the present study, several lines of evidence support a locus on 1q43-44. Marker D1S547 met the criterion for further interest in both two-point and multipoint calculations in our recent second-generation genomic screen (HLOD ¼ 2.17; Z ¼ 3.38). 2 Nearby markers have also demonstrated suggestive linkage and/or association in several other MS screens conducted in a variety of study populations. [4] [5] [6] [7] [8] There is also evidence for linkage to 1q43-44 in the autoimmune diseases rheumatoid arthritis 9-11 and systemic lupus erythematosus, [12] [13] [14] [15] suggesting the potential presence of a gene for general autoimmune processes in this region. Interestingly, all of these markers demonstrating linkage in the MS, rheumatoid arthritis, and systemic lupus erythematosus screens are within 6 Mb of the peak marker from our genomic screen and follow-up. However, none of the SNPs chosen for this analysis reside in or very near any obvious candidate gene for autoimmunity.
The OSA method proved to be especially useful in regions failing to demonstrate evidence of linkage in the overall data set. The potential for OSA was initially illustrated with breast cancer data, where linkage to the chromosome 17q region containing BRCA1 was identified when ranking families by mean age of onset. 16 The OSA method has subsequently been applied to data sets for Alzheimer disease, autism, age-related macular degeneration, type 2 diabetes and prostate cancer. [17] [18] [19] [20] [21] [22] [23] This study confirmed several chromosomal regions warranting further investigation in the search for genes conferring susceptibility to MS. Owing to the continued evidence of linkage and the consistency of data sets from which these linkage signals arise, we are particularly interested in pursuing chromosome regions 1q44, 2q35, and 18p11. Further elucidation of the genetic effects in these regions of linkage as well as HLA-DR will serve as crucial tools in unraveling the genetic heterogeneity of MS. Figure 3 Chromosome 18 OSA analysis. For the OSA analysis, families were ranked by family-specific LOD scores for HLA-DR (Low to High or High to Low) and family-specific HLA-DR2 allele weights (Low to High or High to Low). Because chromosome 1 demonstrated compelling evidence of linkage after follow-up, OSA analysis was also performed for chromosomes 2q, 9q, 13q, 16q, 18p and 19q with families ranked by chromosome 1 LOD* scores (Low to High or High to Low). Optimal OSA subsets were identified using OSA software. 16 Corresponding LOD scores for OSA subsets were calculated in GENEHUNTER-PLUS and are reported as maxLOD scores. 32, 33 Statistically significant increases in LOD scores for OSA subsets were identified by P-values o0.05.
